A Phase IV Prospective, Multicentre, Randomized, Open-Label Trial to Assess the Efficacy and Safety of GONAL f at a Dose Based on Subject Baseline Characteristics Determined According to the CONSORT Calculator Compared With a Standard Dose of GONAL f 150 IU Per Day for Ovarian Stimulation in Women Undergoing Assisted Reproductive Technology (ART).
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2013
At a glance
- Drugs Follitropin alfa (Primary)
- Indications Infertility
- Focus Therapeutic Use
- Acronyms CONSORT RCT in ART
- Sponsors EMD Serono
- 28 Jul 2012 Additional location (England) added as reported by European Clinical Trials Database.
- 23 Jun 2012 Additional locations added as reported by European Clinical Trials Database.
- 24 Mar 2012 This trial is recruiting in Spain and France.